menu ☰
menu ˟

[Department of Error] Department of Error

06 Jul 2019

Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019; 394: 39–50—In this Article, in panel C of figure 2, the p value for the proportion of patients achieving the HbA1c target of less than 7·0% for oral semaglutide versus liraglutide by use of the trial product estimand should have been “p=0·0620”; in table 2, the p value for the estimated odds ratio for HbA1c ≤·5% at 26 weeks for the liraglutide group by use of the trial product estimand should have been “p=0·1503”, the 95% CI range for the estimated odds ratio for bodyweight loss ≥10% at 26 weeks in the liraglutide group by use of the trial product estimand should have been “(1·52 to 5·05)”, and the estimated odds ratio for bodyweight loss ≥10% at 52 weeks in the placebo group by use of the trial product estimand should have been “8·39 (2·79 to 25·26); p=0·0002”.

Click here to view the full article which appeared in The Lancet